Breast carcinoma remains the most frequently diagnosed cancer worldwide and presents a significant public health burden. The treatment of breast cancer typically includes surgery, followed by therapies like chemotherapy, radiation therapy, hormone therapy, targeted drug therapy, and immunotherapy to eliminate cancer cells and prevent recurrence. Aim of our study was to evaluate clinical and radiological features with survival rate of post treated breast cancer patients. Method: A retrospective study was conducted in the Department of Radiodiagnosis, Imaging, and Nuclear Medicine at BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal. The study period spanned from July 9, 2023, to January 16, 2024, during which clinical and radiological data were collected from patient history, medical records and Contrast Enhanced Computed Tomography (CECT) finding during follow-up after complete treatment. The data were analyzed using IBM SPSS statistics version 25.0. Result: Total 258 post-treated breast cancer patients were enrolled in our study in which 255 (98.8%) of participants were female whereas 3 (1.2%) were male patients. The age group of our study was 23 – 83 years where mean age 48.26 years with a standard deviation (SD) ±11.08 years. Among total population, 110 (44.4%) patients showed normal post-treatment findings, followed with pulmonary fibrosis in 26 patients (10.5%), non-neoplastic skin thickening was noted in 20 patients (8.1%), pleural effusion in 14 patients (5.6%), seroma in the axilla and mastectomy bed in 13 patients (5.2%), pulmonary atelectasis in 12 patients (4.8%), patchy opacity in 9 patients (3.6%), ground glass opacification in 8 patients (3.2%), and reactive lymphadenopathy in 6 patients (2.4%). The most commonly used chemotherapy regimen was Adriamycin/Cytoxan/Taxol (AC-T) were 125 (51.4%), which showed a recurrence rate of 17.6% whereas patients treated with Fluorouracil (5-FU), Epirubicin, and Cyclophosphamide (FEC) were 68 (28.0%) had a lower recurrence rate (13.2%) with the longest median survival time was 1570.5 days. Conclusion: CECT imaging provides invaluable information in detecting local recurrences, particularly when mammographic findings were inconclusive. These findings highlight the importance of personalized treatment approaches, integrating advanced imaging techniques and tailored follow-up care to enhance long-term outcomes for breast cancer survivors, particularly in resource-limited settings. This study also accomplished that prognosis of breast cancer patients who were treated on time with proper treatment guidelines were good.

Keywords: Breast Carcinoma; Contrast Enhanced Computed Tomography (CECT); Modified Radical Mastectomy (MRM); Chemotherapy (CT); Radiotherapy (RT); Metastases; Survival Rate

References

1. Shrestha R., et al. “Breast Cancer among Cancer Patients Visiting the Department of Internal Medicine of a Tertiary Centre”. JNMA Journal of Nepal Medical Association 270 (2024): 64-67.
2. Arnold M., et al. “Current and future burden of breast cancer: Global statistics for 2020 and 2040”. Breast 66 (2022): 15-23.
3. Załuska-Kusz J and Litwiniuk M. “Follow-up after breast cancer treatment”. Reports of Practical Oncology and Radiotherapy 5 (2022): 875-880.
4. Hagay C., et al. “Contrast-enhanced CT: value for diagnosing local breast cancer recurrence after conservative treatment”. Radiology3 (1996): 631-638.
5. Shrestha R., et al. “Breast Cancer among Cancer Patients Visiting the Department of Internal Medicine of a Tertiary Centre”. JNMA Journal of Nepal Medical Association 270 (2024): 64-67.
6. Sapkota G., et al. “Prevalence of Breast Cancer in different geographical regions: A Retrospective Study from Central Nepal”. Nepalese Journal of Cancer1 (2022): 101-105.
7. Weigelt B., et al. “Histological types of breast cancer: how special are they?” Molecular Oncology 3 (2010): 192-208.
8. Acharya SC., et al. “Clinical Profile of Patients Presenting with Breast Cancer in Nepal”. Kathmandu University Medical Journal3 (2012): 3-7.
9. El Saghir NS., et al. “Improved Survival of Young Patients With Breast Cancer 40 Years and Younger at Diagnosis”. JCO Global Oncology 9 (2023): e2200354.
10. Shimomura A., et al. “Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan”. Breast Cancer 4 (2024): 581-592.
11. Petrelli F., et al. “Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials”. Medicina (Kaunas) 2 (2024): 341.
12. Where cancer spreads. National Cancer Institute. U.S. National Institutes of Health (2024).
13. Chen MT., et al. “Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis”. Scientific Reports 1 (2017): 9254.
14. Polyzos A., et al. “FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)”. Breast Cancer Res Treat1 (2010): 95-104.

Citation

Citation: Adhikari Ganga D.,et al. “Clinical and Radiological Features of Post Treated Breast Carcinoma Patients: A Single Centre Descriptive Study".Acta Scientific Cancer Biology 9.3 (2025): 65-83.

Copyright

Copyright: © 2025 Adhikari Ganga D.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.